{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:57Z","timestamp":1793914077511,"version":"4.8.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30GM145500"],"award-info":[{"award-number":["P30GM145500"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006418","name":"Brown University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012299","name":"Brown University Warren Alpert Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017064","name":"Rhode Island Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201201","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:50:46Z","timestamp":1775667046000},"page":"201201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-794X","authenticated-orcid":false,"given":"Moon Jung","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Young","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedia","family":"Akosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Raufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-6722","authenticated-orcid":false,"given":"Olin D.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201201_bib1","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"374","author":"McKinnon","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.omton.2026.201201_bib2","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-0-12-802997-8.00023-2","article-title":"Glioblastoma","volume":"134","author":"Wirsching","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.omton.2026.201201_bib4","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.21873\/anticanres.17295","article-title":"Understanding the Genomic Landscape of Glioblastoma: Opportunities for Targeted Therapies","volume":"44","author":"Zeller","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137174","article-title":"CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201201_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201201_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201201_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201201_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneurol.2015.139","article-title":"Prospects of immune checkpoint modulators in the treatment of glioblastoma","volume":"11","author":"Preusser","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omton.2026.201201_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-017-0492-y","article-title":"Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma","volume":"18","author":"Maxwell","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","article-title":"HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors","volume":"16","author":"Ahmed","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.omto.2022.01.002","article-title":"IL-13Ralpha2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma","volume":"24","author":"Xu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201201_bib13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","article-title":"CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges","volume":"20","author":"Bagley","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.2017.77.3192","article-title":"Oncolytic Virotherapy for Malignant Gliomas","volume":"36","author":"Forsyth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib17","article-title":"Immunotherapy for Glioblastoma: Current Progress and Challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201201_bib18","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201201_bib19","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201201_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201201_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/v13071294","article-title":"Oncolytic Viruses for Malignant Glioma: On the Verge of Success?","volume":"13","author":"Suryawanshi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omton.2026.201201_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201201_bib23","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201201_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201201_bib25","first-page":"229","article-title":"CAR NK Cells: The Future Is Now","volume":"7","author":"Raftery","year":"2023","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.omton.2026.201201_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omton.2026.201201_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201201_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201201_bib30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201201_bib31","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201201_bib32","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib33","first-page":"5736","article-title":"Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy","volume":"62","author":"Lamfers","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2026.201201_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/1078-0432.CCR-0609-03","article-title":"Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo","volume":"10","author":"Witlox","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omton.2026.201201_bib37","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201201_bib38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/neuros\/nyx507","article-title":"Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients","volume":"83","author":"Tejada","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.omton.2026.201201_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fonc.2018.00061","article-title":"DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report","volume":"8","author":"Tejada","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201201_bib40","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","article-title":"DNX-2401: an investigational drug for the treatment of recurrent glioblastoma","volume":"28","author":"Philbrick","year":"2019","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.omton.2026.201201_bib41","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2020.11.FOCUS20853","article-title":"Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations","volume":"50","author":"Ene","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.omton.2026.201201_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201201_bib43","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00262-021-02856-0","article-title":"Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma","volume":"70","author":"Huang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201201_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201201_bib45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201201_bib46","article-title":"A 3D spheroid model for glioblastoma","volume":"158","author":"Guyon","year":"2020","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2026.201201_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2021.08.019","article-title":"Three-dimensional culture models to study glioblastoma - current trends and future perspectives","volume":"61","author":"Joseph","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omton.2026.201201_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.omto.2022.04.007","article-title":"Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy","volume":"25","author":"Zhou","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201201_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.trecan.2024.05.002","article-title":"Intracranial CAR-T cell delivery in glioblastoma patients","volume":"10","author":"Vaughn-Beaucaire","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201201_bib50","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Ralpha2 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201201_bib51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201201_bib52","first-page":"538","article-title":"Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.omton.2026.201201_bib53","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/0008-5472.CAN-11-0153","article-title":"Heterogeneity maintenance in glioblastoma: a social network","volume":"71","author":"Bonavia","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201201_bib54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2021.02.014","article-title":"Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors","volume":"82","author":"Lauko","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omton.2026.201201_bib55","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1038\/srep07979","article-title":"The evidence of glioblastoma heterogeneity","volume":"5","author":"Soeda","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201201_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13Ralpha2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:20:32Z","timestamp":1793913632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000779"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201201","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.30.667708","asserted-by":"object"}]},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201201"}}